ReviewFrontiers in microbiology2026
Hyperinflammation and immunomodulation in influenza, SARS-CoV-2 and syncytial respiratory virus infection in adults: from innate immune responses and biomarkers to clinical and therapeutic implications.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza, SARS-CoV2-2 and syncytial respiratory virus infection in adults are major causes of morbidity and mortality. However, the pathophysiological mechanisms underlying these infections remain incompletely understood. Disease severity results from an interaction between viral factors and host responses. Lung damage and respiratory failure are produced by hyperinflammation. Understanding these mechanisms is necessary to improve risk stratification and may guide therapeutic decisions. C- reactive protein (CRP), IL-6, ferritin, and ApoH are relevant biomarkers which can identify inflammatory phenotypes. Antivirals and supportive care are the main approaches for these viral infections. From a therapeutic perspective, broad immunosuppression is unlikely to be optimal, and strategies should focus on selectively modulating harmful inflammation while preserving antiviral immunity. Nevertheless, there is scarce evidence of the best choice of treatment based on the patient's clinical profile and further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.